Margaret Haigh Sebens, MS, CCC-SLP | |
48 Barnett Dr. East, Haines, AK 99827 | |
(907) 321-5103 | |
Not Available |
Full Name | Margaret Haigh Sebens |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 48 Barnett Dr. East, Haines, Alaska |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1609127448 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Margaret Haigh Sebens, MS, CCC-SLP Po Box 1247, Haines, AK 99827-1247 Ph: (907) 321-5103 | Margaret Haigh Sebens, MS, CCC-SLP 48 Barnett Dr. East, Haines, AK 99827 Ph: (907) 321-5103 |
News Archive
The former president will speak about the overhaul Sept. 4 at his presidential library in Little Rock, Ark. Media outlets also explore the activities of two nongovernment groups reaching out to people who will be able to shop for insurance in new online marketplaces opening Oct. 1.
Doctors on the move and domiciliary healthcare workers are changing the way patients are treated and are creating new and exciting opportunities for both medical device manufacturers and the consumer electronics industry, according to research by UK based analysts Wireless Healthcare.
Cell therapy company jCyte is launching a phase 2b clinical trial to test the safety and efficacy of its developmental retinitis pigmentosa (RP) treatment, jCell.
People who have recovered from COVID-19 had a robust antibody response after the first mRNA vaccine dose, but little immune benefit after the second dose, according to new research from the Penn Institute of Immunology. The findings, published today in Science Immunology, suggest only a single vaccine dose may be needed to produce a sufficient antibody response.
› Verified 3 days ago